Context
A leading pharmaceutical company needed to enable secure external collaboration for clinical trials while protecting intellectual property and meeting stringent regulatory requirements (21 CFR Part 11, HIPAA, GDPR). Legacy systems created friction for research partners, risking delays in critical drug development programs.
Our Approach
ResilientTech Advisors architected and delivered the organization’s first secure External Partner Portal serving 14 major pharmaceutical clients. We integrated multi-factor authentication, implemented zero trust access models with granular RBAC, established encrypted API communications for clinical trial data exchange, and designed user experiences that reduced friction while maintaining security controls. The solution balanced usability with compliance requirements across multiple regulatory frameworks.
Impact
- Achieved 200% increase in partner engagement within 26 months
- Processed 1M+ portal visits with zero security incidents
- Reduced partner onboarding time from weeks to hours
- Enabled seamless collaboration on $500M+ in clinical trial programs
- Passed FDA inspections with zero findings related to electronic systems
- Created reusable security architecture deployed across additional business units
Related Services
- Security Engineering & OperationsSaaS Program & Product SecurityCyber Risk & Strategy
“ResilientTech Advisors understood that security can’t get in the way of science. They built a portal that 14 pharmaceutical partners actually wanted to use. We went from friction and delays to more than 1M secure visits in under two years, all while meeting every FDA and regulatory requirement.”
Head of IT, Clinical Development Division
This engagement reflects our ability to balance security rigor with user experience enabling compliant external collaboration without sacrificing speed or usability in high-stakes clinical research environments.